INC Research Holdings (INCR) : Traders are bullish on INC Research Holdings (INCR) as it has outperformed the S&P 500 by a wide margin of 13.74% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.43%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.36% in the last 1 week, and is up 17.57% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 8.39% and the 50-Day Moving Average is 7.48%. INC Research Holdings, Inc. has dropped 7.52% during the last 3-month period . Year-to-Date the stock performance stands at -8.25%.
INC Research Holdings (NASDAQ:INCR): On Fridays trading session , Opening price of the stock was $45.01 with an intraday high of $46.27. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $44.36. However, the stock managed to close at $44.51, a loss of 1.02% for the day. On the previous day, the stock had closed at $44.97. The total traded volume of the day was 1,124,649 shares.
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Companys segment Clinical Development Services offers a variety of clinical development services, including global studies, clinical monitoring, investigator recruitment, patient recruitment, data management and study reports. The Companys segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Companys segment Global Consulting provides consulting services regarding clinical trial regulatory affairs, regulatory consulting services, quality assurance audits and pharmacovigilance consulting, non-clinical consulting and medical writing consulting.